Patient characteristics
| . | Control group . | G-PBSCs group . | P . |
|---|---|---|---|
| Total no. of patients | 28 | 30 | |
| 60-70 y | 20 | 16 | |
| ≥ 71 y | 8 | 14 | .07 |
| Age, y, range (median) | 60-77 (65) | 60-88 (68) | |
| Sex | |||
| Female, n | 11 | 16 | |
| Male, n | 17 | 14 | .3 |
| WHO classification | |||
| AML with recurrent cytogenetic translocations, n | 1 | 0 | |
| AML with t(8;21)(q22;q22) AML1/CBFα/ETO, n | 1 | 0 | |
| AML with multilineage dysplasia, n | 6 | 8 | |
| With prior MDS, n | 2 | 3 | |
| Without prior MDS, n | 4 | 5 | .999 |
| AML with myelodysplastic syndrome, therapy related, n | 0 | 1 | |
| Other types, n | 0 | 1 | |
| AML not otherwise categorized, n | 21 | 21 | |
| AML minimally differentiated, n | 4 | 0 | |
| AML without maturation, n | 1 | 3 | |
| AML with maturation, n | 0 | 6 | |
| Acute myelomonocytic leukemia, n | 10 | 11 | |
| Acute monocytic leukemia, n | 5 | 1 | |
| Acute erythroid leukemia, n | 1 | 0 | |
| WBC count | |||
| < 50 000/L, n | 25 | 27 | |
| ≥ 50 000/L, n | 3 | 3 | .999 |
| High-risk category, n* | 13† | 12‡ | |
| Standard-risk category, n | 15 | 18 | .999 |
| . | Control group . | G-PBSCs group . | P . |
|---|---|---|---|
| Total no. of patients | 28 | 30 | |
| 60-70 y | 20 | 16 | |
| ≥ 71 y | 8 | 14 | .07 |
| Age, y, range (median) | 60-77 (65) | 60-88 (68) | |
| Sex | |||
| Female, n | 11 | 16 | |
| Male, n | 17 | 14 | .3 |
| WHO classification | |||
| AML with recurrent cytogenetic translocations, n | 1 | 0 | |
| AML with t(8;21)(q22;q22) AML1/CBFα/ETO, n | 1 | 0 | |
| AML with multilineage dysplasia, n | 6 | 8 | |
| With prior MDS, n | 2 | 3 | |
| Without prior MDS, n | 4 | 5 | .999 |
| AML with myelodysplastic syndrome, therapy related, n | 0 | 1 | |
| Other types, n | 0 | 1 | |
| AML not otherwise categorized, n | 21 | 21 | |
| AML minimally differentiated, n | 4 | 0 | |
| AML without maturation, n | 1 | 3 | |
| AML with maturation, n | 0 | 6 | |
| Acute myelomonocytic leukemia, n | 10 | 11 | |
| Acute monocytic leukemia, n | 5 | 1 | |
| Acute erythroid leukemia, n | 1 | 0 | |
| WBC count | |||
| < 50 000/L, n | 25 | 27 | |
| ≥ 50 000/L, n | 3 | 3 | .999 |
| High-risk category, n* | 13† | 12‡ | |
| Standard-risk category, n | 15 | 18 | .999 |
GDMI indicates [insert expansion]; WHO, World Health Organization; MDS, myelodysplastic syndrome; and WBC, white blood cell.
ETO gene expression.
Four patients exhibited complex cytogenetic abnormalities, including with ≥ 3 cytogenetic abnormalities (eg, del (7q, −5, −7), t (9,22), q(34,11.2)).
Five patients exhibited complex cytogenetic abnormalities.